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ABSTRACT	  Dry	  eye	  syndrome	  is	  a	  common	  disorder	  provoking	  changes	  in	  tear	  quantity	  and	  composition	   being	   the	   most	   common	   ophthalmic	   manifestation	   of	   systemic	  inflammatory	   diseases.	   Untreated	   dry	   eye	   could	   cause	   increased	   risk	   of	   ocular	  infection,	  corneal	  ulcer	  and	  blindness.	  Only	  a	  few	  drugs	  are	  authorized	  so	  far	  for	  the	   treatment	  of	  dry	  eye	  disease	  and	   the	  possibilities	  of	   evolution	   in	   this	   sector	  are	   immense.	   Accordingly,	   the	   future	   tendency	   is	   towards	   the	   development	   of	  drugs	   to	   control	   the	   inflammation	   or	   stimulate	   the	  mucin	   and	   tear	   secretion.	   A	  significant	  number	  of	  new	  potential	  solutions	  are	  under	  development	  or	  placed	  in	  the	  pharmaceutical	  pipeline,	  promising	  better	  results	  and	   lesser	  side	  effects,	  but	  still	   leaving	  unattended	  the	  main	  causes	  of	  the	  disease.	  In	  this	  article,	  we	  review	  the	   corresponding	   literature,	   recent	   clinical	   trials	   data	   and	   patents	   concerning	  future	  pharmaceutical	   compounds	   for	  dry	  eye	  disease	   treatment,	  presenting	   the	  new	  strategic	  movements	  of	  the	  pharmaceutical	  industry.	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RESUMEN	  
Fármacos	  de	  la	  enfermedad	  de	  ojo	  seco	  actualmente	  en	  evaluación	  en	  ensayos	  
clínicos	  El	  síndrome	  de	  ojo	  seco	  es	  un	  trastorno	  bastante	  común,	  que	  provoca	  cambios	  en	  la	  cantidad	  y	  la	  composición	  de	  la	  lágrima,	  siendo	  la	  manifestación	  oftálmica	  más	  común	   de	   enfermedades	   inflamatorias	   sistémicas.	   El	   ojo	   seco	   no	   tratado	   puede	  provocar	  un	  aumento	  del	  riesgo	  de	  infección	  ocular,	  úlceras	  corneales	  y	  en	  casos	  extremos	  ceguera.	  Actualmente	  sólo	  unos	  pocos	  fármacos	  están	  autorizados	  para	  el	   tratamiento	  de	   la	   enfermedad	   y	   las	   posibilidades	   de	   evolución	   en	   este	   sector	  son	   inmensas.	   La	   tendencia	   del	   futuro	   está	   dirigida	   hacia	   el	   desarrollo	   de	  fármacos	  que	  controlan	  la	   inflamación	  o	  estimulan	  la	  secreción	  de	   las	  mucinas	  y	  del	   componente	   acuoso	   de	   las	   lágrimas.	   Un	   número	   significativo	   de	   nuevos	  compuestos	   están	   en	   desarrollo	   o	   ya	   están	   en	   ensayos	   clínicos,	   con	   aparentes	  mejores	   resultados	   y	   efectos	   secundarios	   menos	   adversos,	   pero	   una	   vez	   más	  dejando	   desatendidas	   las	   principales	   causas	   de	   la	   enfermedad.	   En	   este	   artículo	  revisamos	  la	  literatura	  correspondiente,	  los	  últimos	  datos	  de	  los	  ensayos	  clínicos	  y	   las	  patentes	   relativas	   a	   futuros	   compuestos	   farmacéuticos	  para	   el	   tratamiento	  de	  la	  enfermedad	  del	  ojo	  seco,	  desvelando	  los	  nuevos	  movimientos	  estratégicos	  de	  la	  industria	  farmacéutica.	  
Palabras	  clave:	  Ojo	  seco,	  anti-­‐inflamatorios,	  queratoconjuntivitis	  sicca,	  queratitis	  seca,	  xeroftalmia,	  secreción	  de	  mucinas;	  secreción	  de	  lágrima;	  antiinflamatorios	  no	  esteroideos.	  
INTRODUCTION	  Dry	   eye	   disease	   is	   a	   chronic	   ocular	   disorder	   affecting	   approximately	   10-­‐20%	   of	   the	   population	   worldwide,	   being	   relatively	   frequent	   among	   women	  especially	  after	  the	  menopause	  (1,	  2).	  This	  pathology	  is	  closely	  related	  to	  the	  aging	  and	   it	   is	   progressively	   affecting	   larger	   parts	   of	   the	   population.	   Almost	   everyone	  experiences	  ocular	  irritation	  or	  the	  symptoms	  of	  dry	  eye	  under	  certain	  conditions,	  such	   as	   prolonged	  working	   on	   a	   computer,	   being	   in	   a	   dry	   environment	   or	   after	  using	  certain	  drugs	  (3-­‐5).	  Patients	  with	  autoimmune	  diseases	  are	  prone	  to	  suffer	  from	  dry	   eye	   inflammation,	  which	   is	   a	   key	   factor	   in	   the	   onset	   of	   severe	   dry	   eye	  disease	  (6).	  The	   pathology	   occurs	   when	   the	   ocular	   surface	   tear	   protective	   layer	   is	  weakened	  which	  could	  be	  the	  result	  of	  insufficient	  or	  atypical	  production	  of	  one	  or	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more	  tear	  components	  (7).	  Tear	  film	  forms	  a	  moist	  natural	  barrier	  separating	  eye	  from	   the	   external	  media.	   This	   consistent	   film	   is	   formed	  mainly	   from	   a	   triplet	   of	  aqueous,	   mucous,	   and	   lipid	   layers	   providing	   the	   necessary	   equilibrium	   for	   the	  healthy	  maintenance	  of	   the	  ocular	  surface	  (Figure	  1).	   	  The	  main	   functions	  of	   this	  film	  are:	   lubrication	  of	   the	  ocular	   surface,	   transfer	  of	  nutritional	   elements	   to	   the	  cornea,	  elimination	  of	   foreign	  matter	  and	  cellular	  debris	  generated	  on	   the	  ocular	  surface	  by	  the	  tear	  flow	  and	  the	  blink	  process,	  and	  acting	  as	  the	  first	  line	  of	  defense	  against	  ocular	   surface	   infections	  (8).	  In	  some	  cases,	  the	  imbalance	  of	  the	  tear	  film	  composite	  layers	  leads	   to	   reduced	   tear	   secretion,	  exposure	   of	   the	   eye	   surface,	  dryness	   and	   damage	   of	   the	  surface	   cells	   (6).	   The	   imbalance	  of	  the	  composite	  layers	  could	  be	  caused	   by	   Sjögren’s	   syndrome	  tear	   secretion	  deficiency	   and/or	  tear	   film	   instability	   due	   to	   the	  use	   of	   contact	   lenses	   (6,	   9,	   10).	  Dry	   eye	   syndrome	   types	   are	   classified	   according	   to	   etiologic	   perspectives	   and	  environmental	   influences	  as:	  aqueous	  deficient	  dry	  eye	   (ADDE)	  and	  evaporative-­‐tear	   dry	   eye	   (EDE)	   (6,	   11).	   ADDE	   is	   divided	   to:	   related	   to	   Sjögren’s	   syndrome	  (primary	   and	   secondary)	   and	   non-­‐related	   to	   Sjögren’s	   syndrome	   conditions	  (lacrimal	  disease,	  lacrimal	  obstruction	  and	  malfunctioning	  blinking	  reflex)	  (6).	  EDE	  conditions	  are:	  oil	  deficient,	  lid	  related	  and	  caused	  by	  an	  ocular	  surface	  alteration	  (6).	  Signs	  and	  symptoms	  of	   these	  complications	  can	  vary	   from	  patient	   to	  patient,	  sometimes	   with	   little	   or	   no	   correlation	   between	   them,	   even	   though	   they	   are	  generally	   related	   to	   the	   tear	   film	   composition.	   The	   signs	   and	   symptoms	   could	  include	   keratitis,	   conjunctival	   and	   corneal	   staining,	   redness,	   blurry	   vision,	  decreased	   tear	   film	  break-­‐up	   time,	   decreased	   tear	   production,	   volume,	   and	   flow,	  increased	   conjunctival	   redness,	   excess	   debris	   in	   the	   tear	   film,	   ocular	   dryness,	  ocular	  grittiness,	  ocular	  burning,	  foreign	  body	  sensation	  in	  the	  eye,	  excess	  tearing,	  photophobia,	  ocular	  stinging,	  refractive	  impairment,	  ocular	  sensitivity,	  and	  ocular	  irritation	  (12,	  13).	  	  The	  clinical	  diagnosis	  of	  dry	  eye	  is	  challenging	  since	  dry	  eye	  is	  a	  pathology	  characterized	   by	   an	   extensive	   variety	   of	   signs	   and	   symptoms,	  mentioned	   above,	  related	  to	  ocular	  dryness	  and	  the	  ambiguity	  in	  the	  etiology	  and	  pathophysiology	  of	  
Figure	  1.-­‐	  Tear	  film	  layers.	  
Basilio	  Colligris,	  Jesús	  Pintor	  	  	  
	  	  	  	  	  	  
154	  
the	   disease	   is	   contributing	   to	   the	   difficulty	   of	   a	   precise	   diagnosis	   (14).	  Conventional	   tests	   include	   Schirmer	   test,	   tear	   break-­‐up	   time	   (TBUT)	   and	   ocular	  surface	  staining,	  some	  of	  them	  considered	  as	  invasive	  and	  having	  a	  low	  degree	  of	  standardization.	   Another	   negative	   factor	   is	   the	   lack	   of	   knowledge	   on	   the	  pathophysiology	  of	  the	  disease	  and	  the	  unclear	  symptoms	  which	  could	  be	  confused	  with	   the	   symptoms	   of	   other	   conditions	   ,	   such	   as	   conjunctivochalasis	   (which	   can	  easily	  induce	  an	  unstable	  tear	  film)	  or	  delayed	  tear	  clearance	  (which	  is	  a	  frequent	  cause	  of	   ocular	   irritation)	   (15).	  Other	  negative	   factors	   are	   the	   invasive	  nature	  of	  some	   of	   the	   diagnostic	   tests,	   which	   can	   make	   the	   interpretation	   of	   the	   results	  challenging	   or	   the	   use	   of	   the	   individual	   tests	   in	   very	   dissimilar	   scenarios,	  suggesting	   the	   application	   of	   different	   protocols.	   Nevertheless,	   tear	   film	   is	   a	  dynamic,	  open	  system	  subject	  to	  numerous	  internal	  and	  environmental	  variations,	  leading	  frequently	  to	  misinterpretations	  of	  the	  obtained	  results	  (16).	  In	  conclusion	  the	   variety	   of	   causative	   agents	   and	   the	   high	   number	   of	   ocular	   conditions	   with	  similar	   signs	   and	   symptoms	   make	   an	   accurate,	   differential	   diagnosis	   difficult,	  especially	  due	  to	  lack	  of	  correlation	  between	  signs	  and	  symptoms.	  Accurate	  testing	  and	  diagnosis	  of	  dry	  eye	  is	  crucial	  to	  the	  correct	  management	  of	  the	  condition	  and	  it	   is	   advisable	   the	  use	  of	   combinations	  of	   tests	  and	  sequences.	  Consequently,	   the	  creation	   of	   objective	   tests	   with	   precise	   diagnostic	   value	   is	   essential.	   The	  International	  Dry	  Eye	  Workshop	   (DEWS)	  diagnosis	   subcommittee	   classifies	   tests	  into	   five	   fundamental	   functional	   groups:	   Questionnaires,	   ocular	   surface	   staining	  tests,	   tear	   film	   stability	   tests,	   tear	   volume	   tests	   and	   tests	   to	   measure	   biological	  components	  (2).	  Currently	   there	   are	   only	   a	   few	   pharmaceutical	   treatments	   for	   dry	   eye.	   In	  some	  countries	  like	  Japan,	  are	  commercialized	  more	  DED	  treatment	  drugs	  than	  in	  Europe	  and	  the	  USA	  as	  the	  approval	  rules	  are	  not	  so	  rigorous.	  Another	  important	  factor	   concerning	  DED	   treatment	   is	   that	   in	  most	   of	   the	   cases,	   the	   biotechnology	  companies	   are	   trying	   to	   sort	   out	   the	   problem	   based	   on	   “over	   the	   counter”	  strategies,	   trying	   to	   relieve	   symptoms	   rather	   than	   getting	   to	   the	   cause	   of	   the	  disease.	  Consequently,	  for	  the	  symptomatic	  relief	  of	  dry	  eye	  we	  could	  mention	  the	  following	   treatments	   currently	   used:	   Supplements	   called	   “artificial	   tears”	   which	  are	  synthetic	  lubricants,	  characterized	  by	  hypotonic	  or	  isotonic	  buffered	  solutions	  containing	  electrolytes,	  surfactants	  and	  several	  types	  of	  viscosity	  agents	  (17).	  The	  “artificial	  tears”	  permit	  not	  only	  the	  increase	  of	  tear	  quantity,	  but	  also	  to	  keep	  the	  ocular	  surface	  moistened	  and	  relieve	  discomfort.	  Another	  type	  of	  treatment	  is	  the	  tear	   retention	   devices/implants	   also	   known	   as	   punctal	   plugs.	   They	   have	   been	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developed	   to	   occlude	   the	   lacrimal	   puncta	   and	   they	   can	   be	   absorbable	   and	   non-­‐absorbable	   (18).	   These	  devices	   keep	   tears	   longer	  on	   the	  ocular	   surface	   relieving	  the	   patient’s	   from	   the	   undesirable	   symptoms.	   Other	   type	   of	   treatment	   is	   the	  moisture	   chamber	   spectacles.	   It	   has	   been	   reported	   that	   increased	   periocular	  humidity	  can	  cause	  the	  tear	  film	  lipid	  layer	  to	  thicken	  and	  that	  spectacle	  wearers	  with	   dry	   eye	   have	   a	   longer	   inter-­‐blink	   interval	   than	   the	   non-­‐spectacle	   wearers	  (19).	  Current	  treatments	  are	  mainly	  focused	  on	  addressing	  inflammation	  and	  tear	  restoration	   (20).	   Dry	   eye	   disease	   is	   the	   outcome	   of	   many	   factors	   resulting	   in	  inflammation	   of	   cornea	   and	   conjunctiva.	   The	   dysfunction	   of	   the	   tear	   secretory	  glands	   leads	   to	   changes	   in	   tear	   composition	   such	   as	   hyper-­‐osmolarity	   which	  stimulates	   the	  production	  of	   inflammatory	  mediators	   on	   the	  ocular	   surface.	  This	  inflammation	   can	   be	   initiated	   either	   by	   chronic	   irritative	   stress	   like	   wearing	  contact	   lens	  wearing	   or	   from	   a	   systemic	   inflammatory	   autoimmune	   disease	   like	  rheumatoid	   arthritis	   (21,	   22).	   Anti-­‐inflammatory	   drugs	   are	   widely	   used	   for	   the	  treatment	   of	   the	   inflammation	  produced	  by	  diseases.	   Topical	   corticosteroids	   can	  relieve	  moderate	   or	   severe	   dry	   eye	   symptoms	   and	   signs	   rapidly	   and	   effectively	  (23).	  Steroids	  on	  the	  other	  hand	  may	  cause	  severe	  side	  effects	  after	  prolonged	  use.	  The	  undesired	  effects	  vary	  from	  bacterial	  or	  fungal	  infection,	  elevated	  intraocular	  pressure	   and	   cataract	   formation.	   Additionally,	   steroids	   suppress	   locally	   the	  immune	  response	  in	  patients	  with	  already	  compromised	  ocular	  surface.	  Therefore,	  steroids	  are	  typically	  used	  only	  for	  a	  limited	  period	  of	  time	  in	  dry	  eye	  patients	  (20).	  Due	   to	   the	   above-­‐mentioned	   reasons,	   non-­‐steroidal	   anti-­‐inflammatory	   drugs	  (NSAID)	   credited	   as	   causing	   less	   severe	   side	   effects	   are	   recently	   evaluated	   as	   a	  potential	   dry	   eye	   treatment.	   The	   NSAIDs	   could	   decrease	   inflammation	   and	   eye	  discomfort	   due	   to	   their	   analgesic	   effect,	   but	   they	   might	   induce	   DED	   decreasing	  sensitivity.	   In	  2002	  U.S.	  Food	  and	  Drug	  Administration	   (FDA)	  approved	   the	  drug	  
RESTASIS®	  of	  the	  company	  Allergan	  as	  the	  first	  prescription	  medicine	  capable	  to	  increase	   tear	   production	   (24).	   Topical	   RESTASIS®	   is	   an	   ophthalmic	   emulsion	  containing	   cyclosporine	   0.05%.	  Other	   types	   of	   drug	   used	   are	   the	   antibiotics	   like	  azithromycin,	   and	   tetracycline.	   Furthermore,	   some	   research	   groups	   are	   studying	  the	  use	  of	  serum	  tears	  and	  the	  intense	  pulse	  light	  as	  potential	  treatments	  (20).	  On	  the	  following	  pages,	  we	  present	  some	  future	  treatments	  currently	  passing	  clinical	  trials.	  
AL-­‐2178/RIMEXOLONE	  AL-­‐2178/Rimexolone	   1%	   (Figure	   2)	   is	   a	   glucocorticoid	   steroid	   developed	  by	   Alcon,	   as	   a	   treatment	   for	   dry	   eye	   disease.	   Rimexolone	   inhibits	   T-­‐cell	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proliferation	  as	  well	  as	  cytokine	  production	  of	  activated	  CD4+	  T-­‐cells	   in	  a	  similar	  manner	  to	  dexamethasone	  (25).	  The	  compound	  passed	  successfully	  from	  Phase	  III	  clinical	  trials	  (ClinicalTrials.gov	  Identifier:	  NCT00471419)	  in	  May	  2007	  and	  now	  is	  marketed	   as	   a	   1%	   eye	   drop	   suspension	   under	   the	   trade	   name	   Vexol	   by	   Alcon	  Laboratories	  (26).	  	  
LX214/VOCLOSPORIN	  LX214-­‐voclosporin	  (Figure	  3)	  is	  an	  immunosuppressant	  drug	  developed	  by	  Isotechnika	  and	  Lux	  Biosciences.	  Voclosporin	   is	   a	   calcineurin	   inhibitor,	   analog	  of	  cyclosporin	   with	   enhanced	   action	   against	   calcineurin	   and	   a	   greater	   metabolic	  stability.	  It	  is	  already	  used	  as	  a	  treatment	  of	  various	  forms	  of	  non-­‐infectious	  uveitis	  (27).	   The	   two	   companies	   are	   evaluating	   voclosporin	   ophthalmic	   solution	   as	   a	  treatment	  for	  dry	  eye	  disease	  in	  a	  Phase	  I	  clinical	  trial	  (ClinicalTrials.gov	  Identifier:	  NCT00851734),	  but	  did	  not	  publish	  results	  over	  its	  efficacy	  (28).	  
TOFACITINIB	  Pfizer	  Inc.	  developed	  a	  JAK	  inhibitor	  called	  Tofacitinib	  (formerly	  CP-­‐690550	  -­‐	   Tasocitinib)	   (Figure	   4)	   capable	   to	   interfere	   the	   JAK-­‐STAT	   signaling	   pathway,	  which	   transmits	   extracellular	   information	   into	   the	   cell	   nucleus,	   influencing	   DNA	  transcription	   (29).	   The	   company	   concluded	   phase	   I/II	   trials	   (ClinicalTrials.gov	  Identifier:	   NCT00784719)	   in	   patients	   for	   various	   disorders	   including	   dry	   eye	  disease.	  The	  trials	  demonstrated	  improvement	  in	  the	  signs	  and	  symptoms	  on	  dry	  eye	  patients	   and	   the	  use	  of	   the	  drug	  was	  well	   tolerated	   and	  without	   severe	   side	  effects	  (30).	  Huang	  and	  colleagues	  conducted	  a	  study	  to	  82	  patients	  with	  moderate	  to	   severe	   dry	   eye	   disease,	   treated	   for	   eight	   weeks	   with	   0.0001%	   to	   0.005%	  
tofacitinib	  once	  or	  twice	  daily.	  The	  patients	  showed	  reduction	  in	  conjunctival	  cell	  surface	   HLA-­‐DR	   expression,	   tear	   levels	   of	   pro-­‐inflammatory	   cytokines	   and	  inflammation	  markers.	  The	  markers	   in	   tears	   included	  MMP-­‐9,	   IL-­‐15,	   IL-­‐17A,	   and	  IL-­‐12p70	  (31).	  	  
NUTRILARM®-­‐OMEGA-­‐3	  AND	  OMEGA	  6	  FATTY	  ACIDS-­‐T1675	  Omega-­‐3	  and	  omega-­‐6	  essential	  fatty	  acids	  (EFA)	  are	  the	  origin	  of	  a	  family	  of	  compounds	  called	  eicosanoids.	  Eicosanoids	  are	  signaling	  molecules	  produced	  by	  the	   oxidation	   of	   20-­‐carbon	   fatty	   acids	   and	   they	   are	   mediators	   of	   various	  inflammatory	   processes.	   In	   general,	   the	   omega-­‐3	   derived	   compounds,	   systemic	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linoleic	  (LA)	  and	  gamma-­‐linolenic	  acid	  (GLA)	  are	  reducing	  eye	   inflammation,	  and	  n-­‐6	   pathway	   eicosanoids	   are	   considered	   as	   promoting	   inflammation	   (32,	   33).	  Omega-­‐3	   and	   omega-­‐6	   EFAs	   are	   used	   for	   dry	   eye	   treatment	   due	   to	   their	   anti-­‐inflammatory	   effects	   such	   as	   the	   drug	  Nutrilarm®	   of	   the	   French	   company	   Théa	  Laboratoires,	   which	   is	   already	   commercialized	   in	   Europe.	   This	   medicine	   uses	   a	  supplementation	   of	   omega-­‐3	   and	   omega-­‐6	   fatty	   acids,	   which	   according	   to	   the	  company	   reduce	   expression	   of	   the	   conjunctival	   inflammatory	   marker	   human	  leucocyte	   antigen-­‐DR	   (HLA-­‐DR)	   and	   may	   help	   improving	   DED	   symptoms.	   The	  compound	   past	   in	   2006	   from	   Phase	   II	   clinical	   trials	   in	   US	   (ClinicalTrials.gov	  Identifier:	   NCT00357201)	   but	   the	   company	   decided	   to	   continue	   the	   pre-­‐clinical	  development	  to	  resolve	  efficacy	  and	  doses	  issues	  (34-­‐36).	  
ORAL	  OMEGA-­‐3-­‐ACID	  ETHYLESTERS	  Pennsylvania	   State	   University	   and	   the	   American	   Society	   of	   Cataract	   and	  Refractive	   Surgery	   Foundation	   (ClinicalTrials.gov	   Identifier:	   NCT01107964)	  started	  in	  April	  2010	  a	  clinical	  study,	  based	  on	  the	  hypothesis	  that	  oral	  omega-­‐3-­‐acid	   ethyl	   esters	   (Lovaza,	   GlaxoSmithKline)	   will	   decrease	   the	   dry-­‐eye	   related	  symptoms	   as	   well	   as	   clinical	   markers	   associated	   to	   dry	   eye	   disease.	   The	  preliminary	  results	  of	  the	  study	  are	  positive	  but	  more	  research	  is	  needed	  to	  define	  the	  composition	  and	  dosing	  of	  the	  treatment.	  From	  the	  results	  it	  was	  confirmed	  the	  relationship	   between	   EFA	   supplementation	   and	   improvement	   in	   dry	   eye	  symptoms	  in	  patients	  (37).	  Nevertheless	  before	  any	  anti-­‐inflammatory	  therapy	  is	  necessary	  a	  detailed	  examination	  of	  a	  patient	  due	  to	  the	  complexity	  of	  the	  disease	  and	  to	  provide	  individual	  and	  successful	  treatment	  (38).	  	  
SECUKINUMAB	  AND	  CANAKINUMAB	  Novartis	   Pharmaceuticals	   Inc.	   presented	   two	   novel	   antibodies,	  Secukinumab	   (AIN457)	   and	   Canakinumab	   (ACZ885).	   Secukinumab	   is	   a	   fully	  human	  monoclonal	  antibody	  designed	  to	  bind	  selectively,	  inhibiting	  the	  member	  A	  of	   interleukin	   17cytokine	   family,	   a	   key	   driver	   of	   immune-­‐mediated	   diseases.	  Canakinumab	   is	   a	   fully	  human	  monoclonal	   antibody,	   inhibiting	   solely	   interleukin	  1β	  (IL-­‐1β),	  the	  form	  of	  the	  interleukin-­‐1	  protein	  that	  is	  the	  main	  cause	  of	  various	  inflammatory	  diseases	  (39).	  Currently	  both	  antibodies	  are	  under	  development	  as	  treatments	   of	   a	   wide	   range	   of	   auto	   inflammatory	   diseases.	   In	   November	   2010	  Novartis	  started	  a	  Phase	  II	  study	  on	  effects	  of	  a	  single	  intravenous	  administration	  of	   Secukinumab	   10	   mg/kg	   or	   Canakinumab	   10	   mg/kg	   on	   72	   dry	   eye	   patients	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(ClinicalTrials.gov	  Identifier:	  NCT01250171).	  The	  study	  reports	  suggest	  that	  both	  substances	  are	  well	  tolerated	  in	  most	  patients,	  and	  no	  serious	  adverse	  effects	  have	  been	  reported.	  The	  drugs	  provide	  significant	  advantages	  over	  existing	  competitive	  therapies,	   including	   bimonthly	   administration	   and	   an	   approved	   use	   in	   children	  (40-­‐42).	  
MIM-­‐D3	  Mimetogen	   Pharmaceuticals	   Inc.	   is	   developing	   MIM-­‐D3,	   a	   small	   molecule	  mimicking	   the	  nerve	  growth	   factor	   (NGF)	  activity	   (Figure	  5).	  NGF	   stimulates	   the	  conjunctival	   cell	   glycoconjugate	   secretion	   and	  during	   in	   vivo	   trials	   demonstrated	  therapeutic	  efficacy	  on	  dry	  eye	  disease	  (43).	  NGF	  plays	  an	  important	  role	  in	  ocular	  surface	   maintenance,	   corneal	   wound	   healing,	   displaying	   a	   mucin	   secretagogue	  activity	   in	   conjunctival	   cells	   (44).	   Jain	   and	   colleagues	   during	   evaluation	   studies	  demonstrated	   that	   a	   1%	   MIM-­‐D3	   dose	   increased	   glycoconjugate	   concentration,	  improving	   the	   quality	   and	   stability	   of	   tear	   film	   and	   the	   healing	   on	   the	   ocular	  surface	  in	  dry	  eye	  (45).	  Mimetogen	  conducted	  Phase	  II	  safety	  and	  efficacy	  studies	  (ClinicalTrials.gov	   Identifier:	   NCT01257607)	   from	   December	   2010	   to	   October	  2012,	  on	  150	  patients	  with	  the	  application	  of	  1%	  MIM-­‐D3	  and	  5%	  MIM-­‐D3	  for	  28	  days.	   Unfortunately	   the	   target	   primary	   endpoints	   were	   not	   met	   completely.	  Despite	   this	   negative	   development	   the	   company	   continues	   the	   development	  considering	  MIM-­‐D3	  as	  a	  potent	  compound	  (46).	  
DIFLUPREDNATE	  Alcon	   is	   evaluating	   the	   corticosteroid	   Difluprednate-­‐Durezol,	   a	   butyrate	  ester	   of	   6(alpha),9(alpha)-­‐difluoro	   prednisolone	   acetate	   as	   a	   potential	   treatment	  for	   dry	   eye	   disease	   (Figure	   6)	   (47).	   This	   corticosteroid	   is	   preventing	   the	  phospholipid	   release	   and	   decreases	   the	   eosinophil	   action.	   Durezol	   received	  approval	   from	   the	   FDA	   in	   2008	   as	   the	   first	   ophthalmic	   steroid	   for	   the	  postoperative	   inflammation	   and	   pain.	   Alcon	   started	   clinical	   trials	   Phase	   II	  (ClinicalTrials.gov	  Identifier:	  NCT01276223)	  in	  January	  2011	  for	  the	  Difluprednate	  ophthalmic	  emulsion	  0.05%,	  one	  drop	  in	  each	  eye	  twice	  per	  day,	  on	  726	  patients,	  as	   an	   anti-­‐inflammatory	   treatment	   of	   dry	   eye	   disease.	   Mulki	   and	   colleagues	   are	  suggesting	   that	   difluprednate	   0.05%	   ophthalmic	   emulsion	   exhibits	   enhanced	  penetration,	   decent	   bioavailability,	   rapid	   local	   metabolism	   and	   strong	   efficacy,	  with	  a	  low	  incidence	  of	  adverse	  effects	  and	  a	  comparable	  safety	  profile	  (48).	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CIS-­‐UROCANIC	  ACID	  	  LaurantisPharma	   Ltd	   and	   Kuopio	   University	   Hospital	   are	   developing	   eye	  drops	   containing	   Cis-­‐urocanic	   acid	   (cis-­‐UCA)	   as	   treatment	   for	   ocular	   surface	  inflammation	  associated	  with	  moderate	  to	  severe	  dry	  eye	  syndrome.	  Cis-­‐urocanic	  acid	   inhibits	   the	   SAPK/JNK	   signaling	   pathway	   in	   ultraviolet	   B	   (UV-­‐B)	   exposed	  human	   corneal	   epithelial	   cells	   in	   vitro,	   having	   important	   implications	   in	   the	  management	  of	  inflammatory	  eye	  conditions	  since	  chronic	  stress	  is	  directly	  linked	  to	  cytotoxicity	  in	  epithelial	  cells.	  During	  tests	  it	  was	  demonstrated	  that	  is	  inhibiting	  the	  secretion	  of	  pro-­‐inflammatory	  cytokines	  from	  human	  conjunctival	  and	  corneal	  epithelial	   cells	   after	   UV-­‐B-­‐induced	   stress	   reaction	   (49,	   50).	   Preclinical	   studies	   in	  relevant	  animal	  models	  of	  eye	   inflammation	  also	  demonstrated	  that	  cis-­‐UCA	  may	  be	  a	  safer	  and	  more	  effective	  alternative	  to	  current	  drugs	  used	  for	  acute	  and	  long-­‐term	  treatment	  of	  dry	  eye.	  From	  November	  2011	  to	  May	  2012	  Laurantis	  conducted	  Phase	   I	   (ClinicalTrials.gov	   Identifier:	   NCT01476332),	   safety,	   tolerability	   and	  pharmacokinetics	   studies	   of	   0.5%	   and	   2.5%	   Cis-­‐UCA	   eye	   drops	   in	   adult	   healthy	  volunteers.	   The	   results	   are	   not	   published,	   but	   the	   company	   continues	   the	  development	  of	  the	  compound.	  
THYMOSIN	  BETA	  4	  RegeneRx	   Biopharmaceuticals	   is	   developing	   RGN-­‐259	   which	   is	   a	   0.1%	  Thymosin	  Beta	  4	   (Tβ4)	  ophthalmic	  solution	  as	  a	  novel	   therapeutic	   treatment	   for	  dry	  eye	   (51,	  52).	  Thymosin	  Beta	  4	   is	  a	   synthetic	  version	  of	  a	  naturally	  occurring	  peptide,	  used	  clinically	  as	  a	  tissue	  repair	  and	  regeneration	  peptide	  (53).	  In	  human	  body	   is	   a	   protein	   encoded	   by	   the	   TMSB4X	   gene	   (GenBank	   accession	   number:	  NC_000023.10).	   During	   preclinical	   evaluations	   it	   was	   demonstrated	   that	   Tβ4	   is	  promoting	   corneal	   epithelial	   intercellular	   adhesions	   following	   injury	   in	   animal	  models	  of	  dry	  eye	  (54).	  In	  June	  2011	  RegeneRx	  started	  Phase	  II	  safety	  and	  efficacy	  studies	   (ClinicalTrials.gov	   Identifier:	   NCT01387347)	   of	   the	   RGN-­‐259	   ophthalmic	  solution	   in	   patients	   with	   dry	   eye	   syndrome.	   The	   study	   has	   been	   completed	   in	  December	   2012	   and	   in	  ARVO	  2012	   the	   company	   presented	   the	   results,	   claiming	  the	   statistically	   significant	   reduction	   in	   central	   corneal	   fluorescein	   staining	   from	  baseline	   compared	   to	   placebo	   and	   also	   a	   greater	   reduction	   in	   exacerbation	   of	  ocular	  discomfort	  (55).	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BELIMUMAB	  
Belimumab	   is	   a	   human	   monoclonal	   antibody	   inhibiting	   B-­‐cell	   activating	  factor	   (BAFF)	   and	   is	   developed	   by	   the	   University	   of	   Udine	   as	   a	   treatment	   for	  Sjögren’s	   syndrome.	   Sjögren's	   syndrome	   is	   a	   systemic	   autoimmune	   disease	  characterized	  by	  an	  increase	  in	  BAFF	  (BLyS)	  levels	  resulting	  in	  B	  cell	  hyperactivity.	  B	   cells	   are	   involved	   in	   the	   pathogenesis	   of	   SS	   in	   both	   systemic	   and	   glandular	  features,	   and	   B	   cell	   down	   regulation	  may	   lead	   to	   a	   decrease	   of	   disease	   activity.	  Moreover,	   pathogenesis	   of	   SS	   is	   closed	   to	   that	   of	   systemic	   lupus	   erythematosus,	  where	   belimumab	   has	   been	   proven	   to	   be	   effective.	   Currently	   the	   compound	   is	  under	   Phase	   II	   clinical	   trials	   evaluation	   (ClinicalTrials.gov	   Identifier:	  NCT01160666)	  and	  the	  initial	  results	  are	  promising	  (56).	  	  
RITUXIMAB	  
Rituximab	  (CD20)	  is	  developed	  by	  IDEC	  Pharmaceuticals	  as	  a	  treatment	  for	  Sjögren’s	  syndrome.	  CD20	  antigen	  is	  targeting	  cells	  of	  the	  B-­‐cell	  lineage,	  leading	  to	  transient	  blood	  B-­‐cell	  depletion,	  leaving	  aside	  stem	  cells	  (57).	  Rituximab	  is	  already	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administration	   in	  1997	  as	  a	   treatment	  of	  B-­‐cell	   non-­‐Hodgkin	   lymphomas	   resistant	   to	   other	   chemotherapy	   regimens.	   The	  compound	   currently	   is	   tested	   in	   Phase	   III	   clinical	   trials	   (ClinicalTrials.gov	  Identifier:	  NCT00740948)	  to	  study	  the	  tolerance	  and	  efficacy	  of	  rituximab	  injection	  in	  Sjögren’s	  disease	  (58,	  59).	  
LOTEMAX	  Bausch	   &	   Lomb,	   Inc.	   is	   re-­‐purposing	   the	   already	   approved	   drug	   Lotemax	  with	   topical	   cyclosporine	   ophthalmic	   emulsion	   0.05%	   (Restasis)	   as	   a	   possible	  treatment	   of	   dry	   eye.	   Lotemax	   (loteprednoletabonate-­‐LE)	   (Figure	   7)	   (60)	   is	   an	  ester	  corticosteroid	  with	  a	  high	  therapeutic	  index,	  containing	  an	  ester	  rather	  than	  a	  ketone,	  at	  carbon-­‐20	  of	   the	  prednisolone	  core	  structure.	  LE	   is	   indicated	   for	   the	  treatment	   of	   steroid	   responsive	   inflammatory	   conditions	   associated	   to	   the	  palpebral	   and	   bulbar	   conjunctiva,	   cornea,	   and	   anterior	   segment	   of	   the	   globe.	   Its	  mechanism	   of	   action	   is	   to	   block	   the	   inflammatory	   mediators	   treating	   the	  inflammation	   associated	   with	   the	   dry	   eye	   disease.	   Cyclosporine	   A	   as	   already	  mentioned	  above	  is	  a	  standard	  molecule	  against	  inflammation	  with	  efficacy	  in	  dry	  eye	   disease,	   enhancing	   or	   restoring	   the	   lachrymal	   gland	   secretion	   in	   patients	  suffering	   from	   this	   syndrome	   (61).	   An	   advantage	   of	   topical	   loteprednol	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pretreatment	   is	   the	  reduction	  of	  Cyclosporine	  stinging	   in	  chronic	  dry	  eye	  disease	  (62).	   Lotemax	   ophthalmic	   suspension,	   0.5%	   completed	   Phase	   II	   studies	  (ClinicalTrials.gov	  Identifier:	  NCT00560638)	  in	  July	  2011.	  From	  the	  results	  it	  was	  confirmed	   its	  ability	   to	  reduce	   the	  eye	   inflammation	  rapidly,	  causing	   limited	  side	  effects.	  Additionally	  in	  2012	  Wan	  and	  colleagues	  performed	  a	  study	  on	  34	  patients,	  confirming	   the	   efficacy	   of	   topical	   0.5%	   loteprednoletabonate	   ophthalmic	  suspension	  for	  the	  treatment	  of	  moderate	  dry	  eye	  (63).	  	  
ECABET-­‐SODIUM	  Bausch	  &	  Lomb	  Inc.	  is	  developing	  a	  prescription	  eye	  drop	  for	  the	  treatment	  of	   dry	   eye	   syndrome	   called	   Ecabet	   (Accession	   Number:	   DB05265).	  Sulfodehydroabietic	   acid	   monosodium	   salt	   pentahydrate	   or	   ecabet	   sodium,	  represents	   a	   new	   class	   of	   small	   diffusible	   molecules	   capable	   of	   increasing	   the	  quantity	   and	   quality	   of	  mucin	   produced	   by	   conjunctival	   goblet	   cells	   and	   corneal	  epithelia	   (Figure	  8)	   (64).	  This	  ability	  makes	   the	  compound	  quite	   interesting	  as	  a	  treatment	   for	   muco-­‐deficient	   dry	   eye.	   Ecabet	   possible	   mechanism	   of	   action	   is	  through	   the	   targeting	   of	   the	   prostaglandin	   E2	   pathway,	   inhibiting	   the	   pepsin	  formation,	   increasing	  blood	  flow	  and	  downregulating	  the	  reactive	  oxygen	  species	  on	  the	  ocular	  surface.	  (65).	  It	  is	  marketed	  in	  Japan	  by	  Senju	  Pharmaceutical	  as	  an	  oral	  agent	  for	  gastric	  ulcers	  and	  gastritis	  treatment	  (66).	  Bausch	  &	  Lomb	  organized	  from	  April	   2008	   to	   January	   2013	   Phase	   II	   efficacy	   and	   safety	   studies	   for	  Ecabet	  ophthalmic	   solution	   with	   the	   purpose	   of	   treating	   the	   dry	   eye	   syndrome	  (ClinicalTrials.gov	  Identifier:	  NCT00667004)	   in	  183	  patients.	  Bausch	  &	  Lomb	  Inc.	  did	  not	  yet	  distribute	  results	  information.	  	  
BOL-­‐303242-­‐X	  Pharmaceutical	  R&D,	  Bausch	  &	  Lomb	  Inc.,	  presented	  the	  drug	  BOL-­‐303242-­‐X	  (mapracorat)	  (Figure	  9)	  a	  selective	  glucocorticoid	  receptor	  agonist,	  as	  a	  possible	  treatment	   for	   inflammatory	   skin	   and	   eye	  diseases.	   This	   agonist	   is	   binding	   to	   the	  glucocorticoid	   receptor	   with	   an	   affinity	   similar	   to	   dexamethasone.	   Zhang	   and	  colleagues	   demonstrated	   during	   in	   vitro	   and	   in	   vivo	   studies	   that	   BOL-­‐303242-­‐X	  inhibited	  interleukin-­‐1β	  (IL-­‐1β)	  and	  induced	  decreases	  of	  inflammation	  in	  human	  corneal	   epithelial	   cells.	   It	   is	   possible	   that	   BOL-­‐303242-­‐X	   is	   acting	   as	   an	   anti-­‐inflammatory	  agent	  in	  various	  primary	  human	  ocular	  cells	  with	  similar	  activity	  to	  classical	  steroids.	  As	  mechanism	  of	  action	  it	  is	  suggested	  its	  interference	  in	  human	  ocular	  cells	  MAPK	  (p38	  and	  JNK)	  and	  NFκB	  signaling	  pathways	  (67).	  Vollmer	  T.R.	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and	  colleagues	  confirmed	  that	  mapracorat	  exerts	   its	  anti-­‐inflammatory	  effects,	  at	  least	   in	  part,	   by	   augmenting	  MAPK	  phosphatase-­‐1	   (MKP-­‐1)	   expression	   (68).	  The	  compound	   has	   an	   improved	   side-­‐effect	   profile,	   compared	   to	   classical	  glucocorticoids.	  On	  the	  other	  hand	  farther	  research	  is	  necessary	  due	  to	  reports	  of	  skin	  atrophy	  produced	  in	  some	  patients	  (69).	  Bausch	  &	  Lomb	  performed	  Phase	  II	  studies	  on	  350	  patients,	  to	  assess	  the	  safety	  and	  efficacy	  of	  0.3%,	  2%	  BOL-­‐303242-­‐X	   in	   dry	   eye	   syndrome,	   (ClinicalTrials.gov	   Identifier:	   NCT01163643)	   from	   July	  2010	  to	  November	  2012	  but	  did	  not	  publish	  results.	  
AL43546	  AL43546	   is	   an	   ophthalmic	   solution	   developed	   by	   Alcon.	   It	   is	   consisted	   of	  hydroxypropyl	   guar	   galactomannan	   0.15%	   or	   0.25%	   (Figure	   10).	   Guar	  galactomannan	  is	  used	  to	  add	  viscosity	  to	  artificial	  tears.	  In	  September	  2008	  Alcon	  started	   a	   Phase	   II	   clinical	   pharmacological	   study	   of	   AL-­‐43546	   ophthalmic	  compound	  in	  subjects	  with	  shortened	  tear	  film	  break	  up	  time,	  to	  study	  the	  lacrimal	  fluid	  condition	  chronologically	  after	  a	  single	  dose	  of	  AL-­‐43546	  ophthalmic	  solution	  (ClinicalTrials.gov	  Identifier:	  NCT00760045)	  (70).	  The	  results	  were	  not	  published.	  
SIROLIMUS-­‐RAPAMYCIN	  Sirolimus	   is	   an	   antibiotic	   demonstrating	   immunosuppressive	   and	   anti-­‐inflammatory	  properties.	  Its	  mechanism	  of	  action	  is	  to	  block	  T-­‐cell	  activation	  and	  proliferation,	  to	  activate	  p70	  S6	  kinase	  and	  to	  inhibit	  significantly	  the	  production	  of	  Th1	  cytokines	  (IFN	  γ,	  IL-­‐2	  and	  TNF)	  (71).	  Its	  name	  is	  derived	  from	  a	  native	  word	  from	  Easter	   Island,	  Rapi	  Nui	   (Figure	  11).	   Santen	  Pharmaceutical	   is	  working	  with	  subconjunctival	  injections	  of	  sirolimus	  as	  a	  mTOR	  inhibitor	  to	  treat	  dry	  eye	  (72).	  It	  is	  reported	  that	  the	  activation	  of	  rapamycinmTOR	  signaling	  mediates	  nerve	  growth	  factor	   (NGF)	   inducing	   cell	   migration	   (73).	   From	   December	   2008	   to	   July	   2010,	  Santen	  realized	  a	  Phase	  II	  dose-­‐ranging	  clinical	  study	  (ClinicalTrials.gov	  Identifier:	  NCT00814944)	   to	   assess	   the	   safety	   and	   efficacy	   of	   subconjunctival	   injection	   of	  sirolimus	   on	   143	   patients	   with	   dry	   eye	   in	   a	   controlled	   adverse	   environmental	  (CAE)	  model.	  The	  doses	  applied	  were	  220,	  440	  and	  880	  micrograms	  of	  rapamycin.	  The	  results	  indicated	  that	  sirolimus	  is	  safe	  and	  tolerable	  with	  no	  systemic	  adverse	  events	  noted,	  demonstrating	  bioactivity	  as	  immunomodulatory	  and	  corticosteroid-­‐sparing	   agent.	   It	   is	   proved	   capable	   to	   reduce	   vitreous	   haze	   and	   cells,	   improving	  visual	  acuity	  (74).	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ISV-­‐101	  ISV-­‐101	   is	   a	   new	   drug	   of	   the	   company	   InSite	   Vision	   incorporating	   a	   low	  dose	  of	  the	  non-­‐steroidal	  anti-­‐inflammatory	  (NSAID)	  bromfenac	  (Figure	  12)	  and	  a	  flow-­‐able	   mucoadhesive	   polymer	   of	  DuraSite	   technology	   (75).	   This	   combination	  enables	  a	  slow	  release	  of	  bromfenac	  over	  a	  longer	  period	  of	  time.	  Consequently	  the	  eye	   aqueous	   humor	   is	   absorbing	   and	   retains	   a	   higher	   dose	   of	   bromfenac.	   The	  extension	  of	  the	  duration	  of	  drug	  residence	  on	  the	  surface	  of	  the	  eye	  enables	  better	  penetration,	   improving	   efficacy,	   safety	   and	   dosing.	   Initial	   data	   from	   previous	  clinical	   studies	   evaluating	   this	   combination	   demonstrated	   a	   favorable	   safety	  profile.	   The	   company	   started	   Phase	   II	   clinical	   trials	   (ClinicalTrials.gov	   Identifier:	  NCT01478555)	  in	  July	  2012	  on	  150	  patients	  to	  evaluate	  the	  safety,	  tolerability,	  and	  efficacy	  in	  topical	  administration	  of	  different	  dose	  regimens	  of	  the	  ISV-­‐101.	  	  
ESBA-­‐105	  ESBATechdeveloped	   ESBA-­‐105	   a	   single-­‐chain	   antibody	   fragment	   that	  targets	  tumor	  necrosis	  factor	  alpha	  (TNF-­‐α)	  (76).	  Selective	  inhibition	  of	  TNF-­‐α	  has	  the	   potential	   of	   modulating	   the	   inflammatory	   and	   immune	   response.	   Preclinical	  studies	   demonstrated	   that	   topically	   administered	   ESBA105	   attains	   therapeutic	  levels	   in	  both	  the	  anterior	  and	  posterior	  segments	  of	  the	  eye	  without	  a	  need	  of	  a	  penetration	   enhancer.	   Consequently,	   its	   drug	   penetration	   and	   ocular	   bio-­‐distribution	  appear	  highly	  attractive	  for	  clinical	  use	  to	  treat	  TNF-­‐α	  connected	  eye	  diseases	   (77).	   Alcon	   after	   the	   fusion	   with	   ESBATech	   conducted	   Phase	   II	   clinical	  trials	   (ClinicalTrials.gov	   Identifier:	   NCT01338610)	   in	   April	   2011	   up	   to	   February	  2012	   to	   evaluate	   the	   efficacy	  of	  ESBA-­‐105	  10	  mg/mL	   in	  90	  patients	  with	   severe	  dry	  eye	  experiencing	  persistent	  ocular	  discomfort.	  The	  results	  demonstrated	  that	  the	   compound	   topically	   applied	   penetrated	   into	   the	   anterior	   chamber	   of	   the	  human	  eye	  at	  therapeutic	  levels	  (78).	  
DA-­‐6034	  Dong-­‐A	  Pharmaceutical	  Co.,	  Ltd	  is	  developing	  a	  MMP-­‐9	  inhibitor	  called	  DA-­‐6034,	   consisting	   of	   7-­‐carboxymethyloxy-­‐3’,4’,5-­‐trimethoxy	   flavone	   monohydrate	  (Figure	  13)	  as	  possible	  treatment	  for	  dry	  eye.	  DA-­‐6034	  is	  a	  synthetic	  derivative	  of	  eupatilin,	   a	   pharmacologically	   active	   flavone,	   capable	   to	   increase	   secretion	   of	  mucin-­‐like	   glycoprotein.	   It	   may	   increase	   as	   well	   the	   secretion	   of	   some	   mucin	  species	  in	  conjunctiva	  and	  cornea.	  Mucin	  is	  a	  glycoprotein	  lubricating	  component	  of	   tear	   film	   able	   to	   weaken	   moisture	   loss	   from	   tear	   evaporation.	   Choi	   and	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colleagues	   verified	   that	  DA-­‐6034	   at	   concentrations	   above	   100	  microM	   increased	  mucin-­‐like	   glycoprotein	   levels	   in	   animal	   models,	   in	   conjunctival	   and	   corneal	  epithelial	  cells	   (79).	  Furthermore	   in	  human	  conjunctival	  epithelial	  cells,	  DA-­‐6034	  treatment	   in	  doses	  of	  200	  microM	   increased	  mucin	  secretion	  between	   the	   trans-­‐membrane	  mucins	  MUC1,	  MUC2,	  MUC4,	  MUC5AC,	  MUC5B,	   and	  MUC16	   (79).	   Seo	  and	   colleagues	   investigated	   the	   inhibiting	   effect	   of	   DA-­‐6034	   MMP-­‐9	   on	  inflammatory	   cytokines	   and	   the	   activation	   of	   the	   MAPK	   signaling	   pathway	   on	  rabbit	  inflammation	  models.	  It	  was	  demonstrated	  that	  DA-­‐6034	  could	  restore	  tear	  function	  and	  inhibit	   inflammatory	  responses	  reducing	  the	  phosphorylation	  of	  Jun	  N-­‐terminal	  kinase	  (JNK)	  and	  p38	  MAPK,	  inhibiting	  the	  nuclear	  factor	  kappa	  B	  cells	  (NF-­‐kB)	  activation	  in	  corneal	  epithelial	  cells	  (80).	  The	  NF-­‐κB	  is	  a	  key	  transcription	  factor	   pathway,	   responsible	   for	   many	   key	   biological	   processes,	   such	   as	  inflammation,	  apoptosis,	  stress	  response,	  corneal	  wound	  healing,	  and	  angiogenesis	  (81).	  The	  company	  Dong-­‐A	  started	  a	  Phase	  II	  study	  of	  DA-­‐6034	  (ClinicalTrials.gov	  Identifier:	  NCT01670357)	  in	  January	  2012	  to	  determine	  the	  efficacy	  and	  safety	  of	  3%	  or	  5%	  DA-­‐6034	  eye	  drops	  on	  150	  patients	  with	  doses	  of	  one	  drop/each	  eye,	  four	  times/day,	  for	  four	  weeks.	  
RX-­‐10045	  Resolvyx	   Pharmaceuticals	   developed	   RX-­‐10045	   (Figure	   14)	   a	   small	   lipid	  mediator	  as	  a	  product	  candidate	   for	   the	   treatment	  of	  ocular	  surface	  and	  anterior	  segment	  diseases	  (82).	  In	  2010	  Celtic	  Therapeutics	  and	  Resolvyx	  Pharmaceuticals	  started	   to	   collaborate	   in	   the	   development	   of	   the	   compound.	   RX-­‐10045	   is	   a	  synthetic	  resolvin	  E1	  (RvE1)	  analog	  formulated	  for	  topical	  application	  treatment	  of	  eye	   disease	   as	   a	   potent	   mediator	   of	   inflammatory	   resolution,	   endogenously	  produced	  by	  the	  human	  body	  from	  omega-­‐3	  fatty	  acid	  (83).	  In	  pre-­‐clinical	  dry	  eye	  models,	  RX-­‐10045	  has	  demonstrated	  potent	   efficacy.	  The	   compound	   successfully	  completed	  a	  Phase	  II	  study	  (ClinicalTrials.gov	  Identifier:	  NCT00799552)	  in	  dry	  eye	  patients	   and	   according	   to	   the	   companies	   it	   demonstrated	   significant	   symptom	  improvement	   from	   baseline	   (as	   assessed	   in	   subject	   diaries),	   and	   performed	  significantly	  better	   than	  placebo	  on	   the	  primary	  endpoint	  of	   the	  worst	   symptom	  score	   with	   a	   75%	   reduction	   in	   controlled	   adverse	   environment-­‐induced	   central	  corneal	  staining	   from	  baseline	  (84).	  RX-­‐10045	  was	  evaluated	   in	  another	  Phase	   II	  study	  (ClinicalTrials.gov	  Identifier:	  NCT01675570)	  from	  August	  2012	  to	  February	  2013	  on	  150	  patients	  for	  the	  treatment	  of	  dry	  eye	  disease	  but	  the	  results	  are	  not	  yet	  published.	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TOBRADEX	  
TobraDex	  was	  approved	  by	  FDA	  as	  dry	  eye	  treatment	  in	  1988.	  TobraDex	  is	  a	  combination	   of	   tobramycin	   and	   dexamethasone	   (Figure	   15).	   Tobramycin	   is	   an	  aminoglycoside	  antibiotic-­‐antibacterial	  derived	  from	  streptomycestenebrarius	  and	  is	  used	  to	  treat	  various	  types	  of	  eye	  infections.	  It	   is	  working	  through	  binding	  to	  a	  site	   on	   the	   bacterial	   30S	   and	   50S	   ribosome,	   preventing	   formation	   of	   the	   70S	  complex,	   inhibiting	  mRNA	  to	  be	  translated	   into	  protein	  (85).	  Dexamethasone	  is	  a	  potent	   synthetic	   member	   of	   the	   glucocorticoid	   class	   of	   steroid	   drugs	   used	   to	  reduce	  the	  inflammation	  and	  relieve	  the	  symptoms	  of	  the	  inflammatory	  eye	  (86).	  The	   combination	  of	   tobramycin/dexamethasone	  might	  be	  an	   interesting	   solution	  for	   dry	   eye	   problems	   caused	   by	   inflammation	   and	   infection.	   Lately	   Alcon	   is	  evaluating	  a	  reformulation	  of	  TobraDex	  decreasing	  the	  amount	  of	  the	  steroid	  (from	  0.1%	   to	   0.05%)	   adding	   an	   inactive	   agent	   (xanthan	   gum),	   to	   stabilize	   the	  combination	  and	  to	  deliver	  more	  of	  each	  drug	  to	  the	  eye.	  The	  composition	  provides	  longer	   ocular	   retention	   for	   enhanced	   ocular	   bioavailability	   of	   tobramycin	   and	  dexamethasone	  and	  improved	  suspension	  of	  dexamethasone	  (87).	  Alcon	  executed	  Phase	   III	   clinical	   trials	   (ClinicalTrials.gov	   Identifier:	  NCT00576251)	   in	   June	  2007	  for	  TobraDex	   ophthalmic	   suspension,	   containing	   0.3%	   of	   tobramycin	   and	   0.05%	  and	  now	  is	  marketing	  the	  product	  as	  an	  antibiotic	  to	  treat	  bacterial	  infections.	  
SYL1001	  The	  Spanish	  biotechnology	   company	  Sylentis	   is	   developing	   the	   compound	  SYL1001,	   which	   is	   decreasing	   the	   pain	   related	   to	   dry	   eye	   disease,	   is	   acting	   by	  targeting	   the	   TRPV1gene	   expression	   on	   the	   ocular	   surface	   (interference	   RNA,	  RNAi)	   (84,	   85).	   This	   is	   an	   interesting	   approach	   as	   gene	   silencing	   is	   an	   attractive	  aspect	   avoiding	   the	   activity	   of	   some	   proteins	   by	   inhibiting	   its	   synthesis.	   In	  November	  2010	  Sylentis	  started	  a	  Phase	  II	  safety/efficacy	  study	  (ClinicalTrials.gov	  Identifier:	   NCT01776658)	   on	   patients	   with	   common	   mild	   to	   moderate	   dry	   eye	  symptoms	  and	  persistent	  daily	  symptoms	  for	  more	  than	  three	  months.	  The	  study	  is	  still	  ongoing	  but	  the	  initial	  results	  are	  very	  promising.	  
R932348	  Rigel	   Pharmaceuticals	   is	   working	   on	   R932348	   2,4-­‐pyrimidinediamine,	   a	  small	   JAK3	  molecule	   inhibitor,	   as	   a	   possible	   treatment	   for	   autoimmune	   diseases	  (Figure	  16)	  (88).	  During	  trials	  it	  was	  observed	  that	  systemic	  levels	  of	  IL-­‐17,	  IL-­‐22,	  IL-­‐23,	  and	  TNF-­‐α	  were	  significantly	  lower	  in	  mice	  receiving	  the	  compound,	  and	  T	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cells	  isolated	  from	  R932348-­‐treated	  mice	  also	  showed	  reduced	  phosphorylation	  of	  Stat5	  after	  stimulation	  with	  IL-­‐2	  (89).	  The	  company	  in	  July	  2013,	  started	  Phase	  II	  safety,	   tolerability	   and	   pharmacokinetics	   studies	   (ClinicalTrials.gov	   Identifier:	  NCT01900249)	  for	  0.2%	  and	  0.5%	  R932348	  ophthalmic	  solution	  in	  patients	  with	  dry	  eye	  disease.	  
EBI-­‐005	  Eleven	  Biotherapeutics	  is	  developing	  chimeric	  IL-­‐1	  receptor	  type	  I	  agonists	  and	   antagonists	   as	   dry	   eye	   treatment.	   These	   non-­‐naturally	   occurring	   cytokine	  domains	  can	  modulate	  cellular	  signaling	  response	  to	  interleukin-­‐1	  receptor	  I	  (IL-­‐1	  RI),	  and	  to	  detect	  and	  or	  even	  bind	  on	  cellular	  receptors(90).	  The	  drug	  started	  in	  December	   2012	   Phase	   I	   multi-­‐center	   clinical	   trials	   (ClinicalTrials.gov	   Identifier:	  NCT01745887)	  with	  the	  name	  EBI-­‐005-­‐2,	  an	  IL-­‐1	  receptor	  blocker,	  single-­‐domain	  protein,	  optimized	   for	   topical	  ocular	  delivery.	  The	  EBI-­‐005	  has	  been	  validated	   in	  clinical	  proof-­‐of-­‐concept	  studies	  in	  which	  IL-­‐1	  blockage	  was	  shown	  to	  be	  safe	  and	  well	   tolerated	  without	  adverse	  side	  effects.	  According	   to	   the	  results	  presented	   in	  ARVO	  2012	   (91)	   it	  was	   created	  by	   combining	   the	   IL-­‐1	   receptor	  binding	   the	   sub-­‐domains	  IL-­‐1β	  and	  IL-­‐1Ra.	  During	  the	  pre-­‐clinical	  trials	  EBI-­‐005	  was	  shown	  more	  active	   than	   topical	   Cyclosporine	   (the	   active	   ingredient	   of	   Restasis™	   ophthalmic	  emulsion	  eye	  drops)	  in	  mouse	  models.	  Topical	  delivery	  resulted	  in	  distribution	  to	  multiple	  eye	  compartments,	  but	  very	  low	  systemic	  exposure	  in	  rabbits	  (F	  <	  0.2%).	  EBI-­‐005	  was	   9°C	  more	   thermally	   stable	   than	   anakinra	   an	   interleukin-­‐1	   receptor	  antagonist	   (92).	  Eleven	  Biotherapeutics	  presented	  promising	  preliminary	   clinical	  data	  from	  the	  trials.	  
CONCLUDING	  REMARKS	  Many	   of	   the	   above	   mentioned	   potential	   drugs	   are	   anti-­‐inflammatory	  compounds	   and	   some	   are	   mucin	   secretagogue,	   promoting	   mucin	   and	   water	  production,	   and	   also	   there	   are	   a	   few	   eye	   lubricants.	   Most	   of	   the	   anti-­‐inflammatories	  are	  corticosteroids	  because	  of	  their	  noteworthy	  anti-­‐inflammatory	  properties	   and	   rapid	   action.	  Normally	   they	   are	  used	   for	   a	   limited	  period	  of	   time	  and	  depending	  on	   the	  severity	  of	   the	  case,	  after	   treatment	   the	  patient	   returns	   to	  the	   initial	   inflammatory	   condition.	   This	   limitation	   makes	   them	   unsuitable	   for	  chronic	   dry	   eye	   therapy	   as	   steroidal	   compounds	   present	   important	   side	   effects,	  such	  as	  increase	  in	  intraocular	  pressure	  and	  posterior	  sub-­‐capsular	  cataract	  (93).	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A	  critical	  point	  to	  highlight	  is	  that	  all	  of	  the	  above-­‐mentioned	  potential	  new	  drugs	  are	  centering	  their	  action	  mainly	  towards	  symptoms,	  controlling	  inflammation	  or	  restoring	  the	  normal	  amount	  of	  tears	  but	  none	  of	  them	  is	  addressing	  the	  causative	  mechanisms	  of	  the	  disease	  leaving	  its	  cause	  unattended.	  Developing	  a	  new	  drug	  for	  the	   treatment	   of	   DED	   has	   become	   a	   key	   target	   for	   the	   pharmaceutical	   industry.	  Even	  though	  dry	  eye	  is	  the	  most	  widespread	  eye	  disorder,	  there	  is	  limited	  offer	  of	  effective	  therapeutic	  agents.	  Dry	  eye	  disease	  is	  not	  a	  life-­‐threatening	  disorder	  and	  its	   symptoms	   are	   not	   severe,	   but	   the	   overarching	   complexity	   of	   the	   syndrome	  makes	   it	  challenging	  to	  manage.	  Many	  of	   the	  candidate	  dry	  eye	  agents	  are	   failing	  FDA	  testing,	  even	  though	  some	  of	   them	  are	  approved	  in	  Asia	  and	  Europe,	  mainly	  because	   of	   the	   tight	   clinical	   trials	   regulations	   in	   the	   USA.	   Other	   reasons	   for	   this	  frequent	  failure	  are	  the	  nature	  of	  the	  syndrome	  and	  the	  lack	  of	  an	  objective	  test	  for	  the	  diagnosis	  of	  the	  severity	  of	  the	  disease,	  because	  usually	  symptoms	  evaluation	  is	   insufficient	   as	   a	   measurement	   factor.	   There	   are	   several	   proposals	   for	   new,	  objective	   tests	  such	  as	  molecular	  markers	  (94,	  95)	  and	   tear	   film	  osmolarity	   tests	  (96,	   97)	   but	   at	   the	  moment	   none	   of	   them	   has	   advanced	   beyond	   the	   pre-­‐clinical	  evaluation.	  Dozens	  of	  companies	  have	  placed	  under	  development	  a	  vast	  variety	  of	  new	   drug	   candidates	   in	   their	   pharmaceutical	   pipelines	   and	  most	   of	   these	   drugs	  have	   already	   approved	   as	   treatment	   for	   other	   diseases	   as	   identical	   biological	  pathways	  can	  be	  active	  in	  different	  ways	  in	  various	  diseases.	  Discovering	  new	  uses	  for	   old	   drugs	   can	   ensure	   important	   financial	   benefits,	   for	   patients	   as	  well	   as	   for	  biotechnology	  companies,	  lowering	  costs	  and	  shortening	  the	  approval	  timelines.	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Drug	   Company	   Properties	   Phase	  AL-­‐2178/Rimexolone	   Alcon/Novartis	   Anti-­‐inflammatory	   Phase	  III	  LX214/Voclosporin	   Isotechnika	   and	   Lux	  
Biosciences	  
Anti-­‐inflammatory	   Phase	  I	  Tofacitinib	   Pfizer	  Inc.	   Anti-­‐inflammatory	   Phase	  II	  Nutrilarm®-­‐Omega-­‐3	  and	  Omega	  6	  fatty	  acids	   ThéaLaboratoire	   Anti-­‐inflammatory	  	   Phase	  II	  Omega-­‐3-­‐acid	  ethyl	  esters	   Lovaza,	  
GlaxoSmithKline	  
Anti-­‐inflammatory	   Phase	  I	  Secukinumab	  and	  Canakinumab	   Novartis	  
Pharmaceuticals	  
Anti-­‐inflammatory	   Phase	  II	  MIM-­‐D3	   Mimetogen	  
Pharmaceuticals	  
Mucin	  secretagogue	   Phase	  II	  Difluprednate-­‐Durezol	   Alcon/Novartis	   Anti-­‐inflammatory	   Phase	  II	  Cis-­‐urocanic	  acid	  	  	   LaurantisPharma	   Anti-­‐inflammatory	   Phase	  I	  Thymosin	  Beta	  4	  	   RegeneRx	  Biopharmaceuticals,	  
Inc.	  
Anti-­‐inflammatory	   Phase	  II	  
Belimumab	   University	  of	  Udine	   Anti-­‐inflammatory	   Phase	  II	  Rituximab	   IDEC	  
Pharmaceuticals	  






ISV-­‐101	  	   InSite	  Vision	   Anti-­‐inflammatory	  	   Phase	  II	  ESBA-­‐105	   Alcon	  and	  ESBATech	   Anti-­‐inflammatory	   Phase	  II	  DA-­‐6034	  	   Dong-­‐A	  Pharmaceutical	  Co.	   Mucin	  secretagogue	   Phase	  II	  RX-­‐10045	   Resolvyx	  
Pharmaceuticals	  
Anti-­‐inflammatory	   Phase	  II	  Tobradex	   (tobramycin/	  dexamethasone)	   Alcon/Novartis	   Anti-­‐inflammatory	   Phase	  I	  SYL1001	   Sylentis	   Lowers	   dry-­‐eye	  
related	  pain	  
Phase	  II	  R932348	   Rigel	  
Pharmaceuticals	  
Anti-­‐inflammatory	   Phase	  II	  EBI-­‐005	   Eleven	  	  
Biotherapeutics	  
Anti-­‐inflammatory	   Phase	  I	  
	   Dry	  eye	  disease	  compounds…	  	  
	  	  	  	  	  	  
169	  
Table	  2.-­‐	  Drug	  Chemical	  Structures.	  
	   Drug	   Chemical	  structure	  Fig.	  2	   AL-­‐2178/	  
Rimexolone	  
	  Fig.	  3	   LX214/	  
Voclosporin	  
	  Fig.	  4	   Tofacitinib	  
	  Fig.	  5	   MIM-­‐D3	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Fig.	  6	   Difluprednate-­‐
Durezol	  
	  Fig.	  7	   Lotemax	  
	  Fig.	  8	   Ecabet	  sodium	  	  
	  Fig.	  9	   BOL-­‐303242-­‐X	  
(mapracorat)	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Fig.	  10	   AL43546/	  
galactomannan	  
	  Fig.	  11	   Sirolimus	  
	  Fig.	  12	   ISV101/	  
bromfenac	  
	  Fig.	  13	   DA-­‐6034	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Fig.	  14	   RX-­‐10045	  




	  Fig.	  16	   R932348	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